Phaseline

Targets › IL12RB1

IL12RB1 (Interleukin-12 receptor subunit beta-1): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. (UniProt, P42701)

Open in Phaseline: the race on IL12RB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kangabio AUSTRALIAKGX101
Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion
IL12, IL12RB1, IL12RB2Phase 1Advanced or Metastatic Solid TumorsJan 2027

Conditions

Advanced or Metastatic Solid Tumors (2)

Modalities

mixed (1)

Companies

Kangabio AUSTRALIA (1)

Related targets

IL12 (1) IL12RB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.